Item 2.02 Results of Operations and Financial Condition.



On May 5, 2023, Pardes Biosciences, Inc. (the Company) issued a press release
announcing its financial results for the quarter ended March 31, 2023. A copy of
the press release is attached as Exhibit 99.1 to this Current Report on Form
8-K.
The information in this Item 2.02, including Exhibit 99.1, is being furnished
and shall not be deemed "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference
into any other filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a
filing.
The Company announces material information to its investors using filings with
the Securities and Exchange Commission and the Company's website at
https://ir.pardesbio.com, as well as press releases, public conference calls,
presentations and webcasts. Therefore, the Company encourages investors, the
media and others interested in the Company to review the information it makes
public in these locations, as such information could be deemed to be material
information.

Item 9.01 Exhibits.

(d) Exhibits

Exhibit No.                                   Description
99.1            Press Release by the Company dated May 5, 2023.
104           Cover Page Interactive Data File (embedded within the Inline XBRL document).



                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses